EverQuote, Inc. (EVER)
NASDAQ: EVER · Real-Time Price · USD
24.14
-0.45 (-1.83%)
Aug 1, 2025, 3:04 PM - Market open
Theseus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts that cover Theseus Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $32.5, which forecasts a 34.63% increase in the stock price over the next year. The lowest target is $29 and the highest is $38.
Price Target: $32.50 (+34.63%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 6, 2025.
Analyst Ratings
The average analyst rating for Theseus Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $29 → $30 | Buy | Maintains | $29 → $30 | +24.28% | May 6, 2025 |
| Needham | Needham | Strong Buy Reiterates $38 | Strong Buy | Reiterates | $38 | +57.42% | May 6, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $25 → $29 | Buy | Maintains | $25 → $29 | +20.13% | Feb 25, 2025 |
| Needham | Needham | Strong Buy Maintains $30 → $38 | Strong Buy | Maintains | $30 → $38 | +57.42% | Feb 25, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $35 → $30 | Strong Buy | Maintains | $35 → $30 | +24.28% | Feb 24, 2025 |
Financial Forecast
Revenue This Year
660.60M
from 500.19M
Increased by 32.07%
Revenue Next Year
733.82M
from 660.60M
Increased by 11.08%
EPS This Year
1.22
from 0.88
Increased by 38.43%
EPS Next Year
1.50
from 1.22
Increased by 23.33%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 699.2M | 779.8M | 869.4M | ||
| Avg | 660.6M | 733.8M | 817.9M | ||
| Low | 625.8M | 688.4M | 758.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 39.8% | 18.0% | 18.5% | ||
| Avg | 32.1% | 11.1% | 11.5% | ||
| Low | 25.1% | 4.2% | 3.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 1.38 | 1.89 | 2.19 |
| Avg | 1.22 | 1.50 | 1.78 |
| Low | 0.97 | 1.00 | 1.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 56.3% | 55.2% | 46.1% |
| Avg | 38.4% | 23.3% | 18.6% |
| Low | 10.2% | -17.9% | 1.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.